American patients facing advanced pancreatic cancer have been offered a more effective treatment after the Food and Drug Administration granted approval on Wednesday to a groundbreaking new therapy against the deadly disease.
Regulators gave expedited authorization to the novel pill, called daraxonrasib, which blocks a mutated protein driving tumor growth in over 90% of pancreatic cancer cases, a scientific approach that had previously eluded pharmaceutical researchers for decades.
